End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC)

Estudo Cleopatra apresentado sob pôster Asco 2019

análise final do Estudo que sem dúvida repercurtiu na vida das mulheres com Câncer de mama HER-2 +3